DAMAGED DNA BINDING PROTEIN 2 PLAYS A ROLE IN BREAST CANCER CELL GROWTH.



Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

Abstract The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemotherapy (SC).Frontline use of FLT3 tyrosine kinase inhibitors (TKIs) midostaurin and sorafenib may con

read more